P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.

Authors: G. Martinelli, A. Santoro, C. Gambacorti-Passerini, S. Vives Polo, S. R. Solomon, S. Mukherjee, E. Lech-Maranda, M. Yair Levy, A. Wierzbowska, M. Calbacho-Robles, G. Marconi, M. Benedetta Giannini, I. Cano, L. Torres Miñana, E. Acuña-Cruz, N. Angelosanto, A. Galleu, S. Baldini, S. Blotta, F. Ravandi, P. Montesinos

Published: 2022-06-23

DOI: 10.1097/01.hs9.0000844968.45342.3d

Source: Full article

---

Abstract

No abstract found.